| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Mar'13 | Mar'12 | Mar'11 | Mar'10 |
|---|---|---|---|---|---|---|---|---|---|
CASH FLOWS FROM OPERATING ACTIVITIES: | |||||||||
Net loss | |||||||||
-196,620 | -139,311 | -157,945 | -208,444 | -227,163 | -30,061 | 24,983 | -113,678 | -45,540 | -39,626 |
Adjustments to reconcile net loss to cash flows from operating activities: | |||||||||
Depreciation and amortization | |||||||||
80,413 | 103,660 | 98,523 | 94,256 | 85,596 | 98,087 | 73,751 | 47,884 | 8,652 | 25,026 |
Share-based compensation expense | |||||||||
100,977 | 105,357 | 83,917 | 94,396 | 97,341 | 59,579 | 34,716 | 28,826 | 19,832 | 13,921 |
Deferred income taxes | |||||||||
-319 | 10,623 | 7,234 | -9,689 | -37,580 | -19,192 | -2,113 | -14,556 | - | - |
Change in the fair value of contingent consideration | |||||||||
-22,800 | -19,600 | 21,600 | 7,900 | -2,300 | - | - | - | - | - |
Gain on sale of investment in Civitas Therapeutics, Inc. | |||||||||
- | - | - | - | - | 29,564 | - | - | - | - |
Gain on the Gainesville Transaction | |||||||||
- | - | - | - | 9,636 | - | - | - | - | - |
Impairment of long-lived assets | |||||||||
- | - | - | - | - | - | 3,346 | 45,800 | - | - |
Loss on debt refinancing | |||||||||
- | -2,298 | - | -2,075 | - | - | -19,670 | - | - | - |
Payment made for debt refinancing | |||||||||
- | 2,251 | - | - | - | - | - | - | - | - |
Impairment of property, plant and equipment | |||||||||
- | 5,746 | - | - | - | - | - | - | - | - |
Impairment of investment in Synchronicity Pharma, Inc. | |||||||||
- | - | 10,471 | - | - | - | - | - | - | - |
Excess tax benefit from share-based compensation | |||||||||
- | - | - | 4,229 | 28,576 | 32,367 | 8,867 | 4,335 | - | - |
Gain on sale of property, plant and equipment | |||||||||
- | - | - | - | 3,272 | 40,099 | -373 | - | - | - |
Gain on sale of investment of Acceleron Pharma Inc. | |||||||||
- | - | - | - | - | 15,296 | - | - | - | - |
Prepayment penalty in connection with debt refinancing | |||||||||
- | - | - | - | - | - | 6,533 | - | - | - |
Principal payments on long-term debt attributable to original issue discount | |||||||||
- | - | - | - | - | - | -2,657 | - | - | - |
Loss on purchase of non-recourse RISPERDAL CONSTA secured 7% Notes | |||||||||
- | - | - | - | - | - | - | - | -841 | - |
Payment or purchase of non-recourse RISPERDAL CONSTA secured 7% notes attributable to original issue discount | |||||||||
- | - | - | - | - | - | - | - | -6,611 | -2,181 |
Other non-cash charges | |||||||||
580 | 979 | 3,471 | 2,936 | 1,351 | 9,192 | 5,325 | 4,342 | 1,861 | 3,833 |
Changes in assets and liabilities: | |||||||||
Receivables | |||||||||
-35,136 | 58,632 | 42,489 | 35,616 | 16,455 | 17,397 | 28,239 | 14,014 | -2,347 | 728 |
Contract assets | |||||||||
5,156 | -880 | - | - | - | - | - | - | - | - |
Inventory | |||||||||
13,077 | 2,665 | 30,191 | 26,381 | -3,687 | 4,210 | - | - | - | - |
Prepaid expenses and other assets | |||||||||
1,784 | 5,990 | 9,506 | 15,014 | -15,931 | 27,027 | - | - | - | - |
Right-of-use assets | |||||||||
-8,399 | - | - | - | - | - | - | - | - | - |
Inventory, prepaid expenses and other assets | |||||||||
- | - | - | - | - | - | 6,577 | 4,879 | -5,211 | 4,037 |
Accounts payable and accrued expenses | |||||||||
34,847 | 46,739 | 72,658 | 45,870 | 76,155 | 56,896 | 19,406 | 15,552 | 6,954 | -2,064 |
Contract liabilities | |||||||||
16,140 | 3,252 | -1,447 | -649 | - | - | - | - | - | - |
Operating lease liabilities | |||||||||
-9,117 | - | - | - | - | - | - | - | - | - |
Deferred revenue | |||||||||
- | - | - | - | -629 | -996 | -3,351 | 6,068 | 635 | -4,753 |
Other long-term liabilities | |||||||||
18 | 8,996 | 6,094 | 4,587 | 3,292 | 3,594 | 3,318 | 508 | -88 | -1,638 |
Cash flows (used in) provided by operating activities | |||||||||
72,077 | 99,281 | 19,190 | -63,802 | -40,360 | 11,139 | 126,551 | -2,482 | -5,906 | -12,247 |
CASH FLOWS FROM INVESTING ACTIVITIES: | |||||||||
Additions of property, plant and equipment | |||||||||
90,942 | 69,431 | 51,300 | 43,657 | 52,877 | 33,651 | 22,217 | 16,988 | 9,401 | 15,787 |
Proceeds from the sale of equipment | |||||||||
900 | 507 | 162 | 194 | 535 | 44,365 | 193 | 35 | 395 | 248 |
Proceeds from contingent consideration | |||||||||
10,000 | - | - | - | - | - | - | - | - | - |
Investment in Acceleron Pharmaceuticals, Inc. | |||||||||
- | - | - | - | - | - | - | 231 | 501 | 8,000 |
Promissory note issued to Civitas Therapeutics, Inc. | |||||||||
- | - | - | - | - | - | 1,116 | - | - | - |
Purchases of investments | |||||||||
277,518 | 397,727 | 431,712 | 375,099 | 508,683 | 642,455 | 303,945 | 228,229 | 370,375 | 465,387 |
Sales and maturities of investments | |||||||||
224,602 | 444,456 | 464,494 | 560,805 | 467,573 | 341,154 | 258,937 | 323,028 | 385,511 | 516,935 |
Acquisition of Rodin Therapeutics, Inc.'s net assets, net of cash acquired | |||||||||
8,875 | - | - | - | - | - | - | 494,774 | - | - |
Investment in Synchronicity Pharma, Inc. | |||||||||
- | - | - | 15,000 | - | - | - | - | - | - |
Net proceeds from the Gainesville Transaction | |||||||||
- | - | - | - | 49,966 | - | - | - | - | - |
Investment in Civitas Therapeutics, Inc. | |||||||||
- | - | - | - | - | 27,190 | - | - | - | - |
Proceeds from the issuance of ordinary shares, net | |||||||||
- | - | - | - | - | 248,406 | - | - | - | - |
Cash flows provided by (used in) investing activities | |||||||||
-141,833 | -22,195 | -18,356 | 127,243 | -43,486 | -263,397 | -68,148 | -417,159 | 5,629 | 28,009 |
CASH FLOWS FROM FINANCING ACTIVITIES: | |||||||||
Proceeds from the issuance of ordinary shares under share-based compensation arrangements | |||||||||
18,925 | 20,877 | 23,517 | 20,308 | 44,969 | 47,577 | 34,360 | 20,864 | 6,158 | 2,593 |
Proceeds from the issuance of long-term debt | |||||||||
- | - | - | - | - | - | 366,483 | 444,100 | - | - |
Employee taxes paid related to net share settlement of equity awards | |||||||||
9,317 | 19,622 | 16,433 | 13,467 | 25,904 | 12,840 | 4,809 | 3,676 | 1,414 | - |
Excess tax benefit from share-based compensation | |||||||||
- | - | - | 4,229 | 28,576 | 32,367 | 8,867 | 4,335 | - | 246 |
Principal payments of long-term debt | |||||||||
2,843 | 743 | - | 3,429 | 6,750 | 6,750 | 449,944 | 775 | - | - |
Payment made for debt refinancing | |||||||||
- | 2,132 | 3,000 | 65,813 | - | - | - | - | - | - |
Payment or purchase of non-recourse RISPERDAL CONSTA secured 7% notes | |||||||||
- | - | - | - | - | - | - | - | -45,397 | -23,486 |
Purchase of ordinary shares for treasury | |||||||||
- | - | - | - | - | - | - | - | - | 2,684 |
Cash flows (used in) provided by financing activities | |||||||||
6,765 | -1,620 | 4,084 | -58,172 | 40,891 | 308,760 | -45,043 | 464,848 | -40,653 | -23,331 |
NET DECREASE IN CASH AND CASH EQUIVALENTS | |||||||||
-62,991 | 75,466 | 4,918 | 5,269 | -42,955 | 56,502 | 13,360 | 45,207 | -40,930 | -7,569 |
SUPPLEMENTAL CASH FLOW DISCLOSURE: | |||||||||
Cash paid for interest | |||||||||
13,254 | 12,526 | 11,143 | 12,458 | 12,323 | 12,489 | 7,656 | 21,658 | 1,684 | 4,918 |
Cash paid for taxes | |||||||||
2,508 | 754 | 2,992 | 5,531 | 705 | 2,799 | 5,921 | 10,068 | 60 | 114 |
Non-cash investing and financing activities: | |||||||||
Purchased capital expenditures included in accounts payable and accrued expenses | |||||||||
13,789 | 11,720 | 11,151 | 5,766 | 6,054 | 3,483 | 2,450 | 3,416 | 424 | 2,798 |
Fair value of warrants received as part of the Gainesville Transaction | |||||||||
- | - | - | - | 2,123 | - | - | - | - | - |
Fair value of contingent consideration received as part of the Gainesville Transaction | |||||||||
- | - | - | - | 57,600 | - | - | - | - | - |
Investment in Civitas Therapeutics, Inc. | |||||||||
- | - | - | - | - | - | - | 1,547 | 1,320 | - |
Issuance of common stock used in the acquisition of Elan Drug Technologies | |||||||||
- | - | - | - | - | - | - | 525,074 | - | - |